Untitled Document

Main Topics of COPD ISTANBUL 2014

  • Are inhaled steroids a risk factor for pneumonia? if so do they impact patient’s outcome?
  • Risk factor for COPD exacerbation hospitalization and re-hospitalization
  • Combination of long-active bronchodilators should be the first line of treatment in patients with COPD group B
  • Treatment of COPD should be start when the disease is moderate and symptomatic
  • Combined pulmonary fibrosis and emphysema
  • Stem cell and regeneration in COPD: is it feasible?
  • Lung function in the diagnosis of COPD
  • Treatment based on phenotypes
  • Functional outcomes for treatment       
  • From simplistic approach to multilateral assessment of COPD management of stable COPD: An update
  • Overlap syndrome in respiratory medicine: Asthma and COPD           
  • Endothelial dysfunction in COPD         
  • Smoking cessation in smokers with COPD
  • Smoking cessation in patients with respiratory diseases
  • Smoking and Asthma
  • Tobacco control in Europe: the role of European Respiratory Society
  • Tobacco control in Europe: The role of respiratory physicians            
  • Follow-up of patients with COPD         
  • Inflammatory biomarkers and exacerbations
  • The budding COPD consortia, foundations, ERICA 
  • COPD and Asthma Phenotypes and Endotypes – how do they overlap?              
  • Beyond promoting guidelines: implementation 
  • How we can influence national strategies
  • Diagnostic and treatment of ACOS (asthma - COPD overlap phenotype )
  • A personalised treatment of COPD: Clinical phenotypes
  • Challenges in the implementation of GOLD strategy             
  • GOLD Grade I-B – physiological characterization
  • Physiological phenotypes of COPD
  • When obesity and COPD collide: Physiological and clinical consequences           
  • PDE inhibitors as treatments for COPD
  • Airway Smooth Muscle:  Novel Therapeutic Targets in COPD
  • Glucocorticoid Insensitivity in Airways Disease
  • What Is the Role of Airway Smooth Muscle Hyperresponsiveness in COPD?
  • Worldwide determinants of COPD underdiagnosis
  • Management and treatment by phenotypes: the new COPD Spanish guidelines
  • Small airways in COPD – no longer silent
  • Inhaled Drug Therapy in COPD – factors to consider
  • Measurement of symptoms according to GOLD 2013 CCQ, CAT, mMRC background    of cut off values
  • COPD ACOS and Asthma in clinical practice cooperation of primary care and secondary care: an integrated care experience with 14000 patients
  • LABA/ICS in COPD pro and con          
  • Update on management of COPD exacerbations
  • Long term antibiotic therapy or macrolide therapy